In a report released today, Aaron Hecht from JMP Securities reiterated a Buy rating on Sabra Healthcare REIT (SBRA – Research Report), with a

Sabra Health Care REIT, Inc. ( NASDAQ: SBRA) Q4 2024 Earnings Conference Call February 20, 2025 1:00 PM ET Lukas Hartwich - EVP, Finance Rick Matros - CEO, President & Chair Talya Nevo-Hacohen - CIO, Treasurer & EVP Mike Costa - CFO

Sabra Healthcare (SBRA) reported $182.35 million in revenue for the quarter ended December 2024, representing a year-over-year increase of 11.6%. EPS of $0.36 for the same period compares to $0.07 a year ago.

Truist Financial analyst Michael Lewis maintained a Hold rating on Sabra Healthcare REIT (SBRA – Research Report) today. The company’s shares

Q4 2024 Management View CEO Rick Matros highlighted that Sabra delivered consistent strong performance in Q4 2024, with senior housing and skilled nursing portfolios showing improvement. SHOP same-store occupancy increased by 80 basis points sequentially,

Sabra (SBRA) delivered FFO and revenue surprises of 0% and 0.48%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

The health care real estate investment trust, based in Tustin, California, posted revenue of $182.3 million in the period, falling short of Street forecasts. Four analysts surveyed by Zacks expected $183.2 million. Sabra expects full-year funds from operations in the range of $1.48 to $1.51 per share.